Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

118.81
Delayed Data
As of Sep 23
 -0.65 / -0.54%
Today’s Change
89.90
Today|||52-Week Range
126.07
+15.66%
Year-to-Date
Ignore Procter & Gamble: Here Are 3 Better Stocks
Sep 25 / MotleyFool.com - Paid Partner Content
Hate Checking Your Portfolio? Try These 2 Stocks
Sep 18 / MotleyFool.com - Paid Partner Content
Biotech Stocks Under $5: 2 to Buy, 1 to Avoid
Sep 24 / MotleyFool.com - Paid Partner Content
Is This New Market the Biggest Investment Idea of the Decade?
Sep 17 / MotleyFool.com - Paid Partner Content
The 5 Most-Sold Stocks of All US Investment Funds
Sep 23 / GuruFocus News - Paid Partner Content
The 3 Best Long-Term Dividend Stocks to Buy Now
Sep 16 / MotleyFool.com - Paid Partner Content
John Paulson Trims Synergy
Sep 23 / GuruFocus News - Paid Partner Content
Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
Sep 16 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
Sep 23 / Zacks.com - Paid Partner Content
Sarepta Shares Soar on News of Key Drug Critic FDA Exit
Sep 15 / Zacks.com - Paid Partner Content
Better Buy: Pfizer Inc. vs. Johnson & Johnson
Sep 23 / MotleyFool.com - Paid Partner Content
Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)
Sep 15 / Zacks.com - Paid Partner Content
Gilead Sciences Inc.'s Biggest Win in 2016 So Far
Sep 22 / MotleyFool.com - Paid Partner Content
FDA Panel Suggests Removing Warning from Pfizer's Chantix
Sep 15 / Zacks.com - Paid Partner Content
Hate Risk? You'll Love These 3 Stocks
Sep 22 / MotleyFool.com - Paid Partner Content
Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep 15 / Zacks.com - Paid Partner Content
Better Buy: Procter & Gamble vs. Johnson & Johnson
Sep 21 / MotleyFool.com - Paid Partner Content
Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi
Sep 14 / Zacks.com - Paid Partner Content
EpiPen Controversy: Mylan's Tough Week Just Keeps Getting Grimmer
Sep 21 / TheStreet.com - Paid Partner Content
You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne
Sep 14 / MotleyFool.com - Paid Partner Content
Move Over, Intuitive Surgical, Here's How Johnson & Johnson and Google Plan to Build ...
Sep 21 / MotleyFool.com - Paid Partner Content
3 Attractive Income Stocks Whose Dividends Could Double
Sep 14 / MotleyFool.com - Paid Partner Content
Big pharma targets drug-resistant superbugs
Sep 20 / FT.com - Paid Partner Content
What the 'Nifty Fifty' can tell us about bond proxies
Sep 14 / FT.com - Paid Partner Content
Johnson & Johnson's Smart (Yet Surprising) Acquisition
Sep 20 / MotleyFool.com - Paid Partner Content
Geron (GERN) at 52-Week Low on Imetelstat Study Update
Sep 13 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Baxter International, AO Smith, Johnson & Johnson, BWX...
Sep 20 / Zacks.com - Paid Partner Content
Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU
Sep 13 / Zacks.com - Paid Partner Content
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap
Sep 19 / GuruFocus News - Paid Partner Content
J&J Files for Single-Tablet Regimen of HIV Drug Prezista in EU
Sep 13 / Zacks.com - Paid Partner Content
Did Warren Buffet Just Call a 2016 Stock Market Crash?
Sep 19 / GuruFocus News - Paid Partner Content
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Sep 13 / Zacks.com - Paid Partner Content
Apple Didn't Waste Billions on Its Buyback Program, but These Companies Did
Sep 19 / MotleyFool.com - Paid Partner Content
5 Blue Chip Stocks You Can Buy Today
Sep 12 / MotleyFool.com - Paid Partner Content
Stock Market News for September 19, 2016
Sep 19 / Zacks.com - Paid Partner Content
Why Geron Corporation Is Plunging Today
Sep 12 / MotleyFool.com - Paid Partner Content
AstraZeneca Diabetes Drug Combination Positive in Phase III
Sep 19 / Zacks.com - Paid Partner Content
Achillion, J&J's HCV Combo Drug Positive in Phase IIa Trial
Sep 12 / Zacks.com - Paid Partner Content
5 Efficient Stocks to Ensure High Yields
Sep 19 / Zacks.com - Paid Partner Content
Gilead Sciencs, Inc. a Takeover Target? It's Not as Crazy As It Sounds
Sep 12 / MotleyFool.com - Paid Partner Content
J&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion
Sep 19 / Zacks.com - Paid Partner Content
Whistleblower lands a $22 million payday from SEC for tips about Monsanto fraud
Aug 31 / CNNMoney.com
When a benchmark can be an illusion
Sep 19 / FT.com - Paid Partner Content